Trial Profile
Phase I Trial of OPB-111077 in Combination With Decitabine and Venetoclax for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; OPB 111077 (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 11 Mar 2024 Status changed from active, no longer recruiting to completed.
- 20 Dec 2022 Planned End Date changed from 25 Nov 2023 to 1 Dec 2023.
- 20 Dec 2022 Planned primary completion date changed from 25 Nov 2022 to 1 Dec 2023.